Core Insights - Scilex Holding Company announced that the U.S. Patent and Trademark Office will issue a new patent related to the treatment of acute pain, further strengthening its intellectual property for ELYXYB®, an FDA-approved oral solution for acute migraine treatment, expected in late 2024 [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, targeting high unmet needs and large market opportunities [4][6] - The company’s commercial products include ZTlido®, ELYXYB®, and Gloperba®, with ELYXYB® being the only FDA-approved ready-to-use oral solution for acute migraine treatment [4][5] Market Potential - The U.S. oral migraine drug market was estimated at $1.8 billion in 2022, while the total acute pain market was approximately $3 billion in 2021 [1][4] - There are about 100 million cases of acute pain in the U.S., indicating a significant market opportunity for non-opioid therapies [1][4] Product Efficacy - ELYXYB® has shown rapid pain relief in clinical studies, with patients experiencing relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in about 50% of patients [2][4] - The product is positioned as a first-line non-opioid therapeutic alternative to opioids and acetaminophen, which are associated with risks such as acute liver failure [1][2] Future Developments - The new patent will enable Scilex to file future applications for acute pain treatments, enhancing its product portfolio and market presence [2][4]

PALO ALTO, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a Master Distributor Agreement with Devart Middle East Food Supplements ("Devart Middle East"), as Master Distributor, and CH Trading Group LLC ("CH Trading Group"), as Territories Distributor, to expan ...

Core Insights - Scilex Holding Company has released its inaugural sustainability report, emphasizing its commitment to environmental stewardship, social responsibility, and governance practices [1][2][3] Environmental Stewardship - The company is dedicated to reducing its environmental footprint, recognizing the global impact of environmental health on everyone [2] Development Excellence - Scilex focuses on developing innovative non-opioid pain management products to address significant unmet medical needs, aiming to improve patient lives [2][3] Social Responsibility - The company emphasizes ethical business practices, respecting employee rights, and fostering an inclusive environment for its workforce and supply chain [2][3] Governance - Scilex promotes transparent corporate governance to ensure accountability and balance the interests of its stakeholders, including patients, suppliers, and employees [2] Strategic Focus - The company's strategy includes advancing patient health, expanding access to non-opioid pain management products, and investing in scientific excellence to expedite the availability of medicines [3]

PALO ALTO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the release of its inaugural sustainability report which highlights sustainability efforts by the company related to its environmental footprint, contributing positively to society, and improving access ...

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its Chief Executive Officer and President, Jaisim Shah, and Executive Chairman, Henry Ji, Ph.D., will ring the Closing Bell at the Nasdaq MarketSite in Times Square, New York, at 4:00 p.m. Eastern ...

The ceremony will be held in celebration of Scilex's launch of GLOPERBA®, an innovative non-opioid product and the first oral liquid medicine for prophylactic treatment of painful gout flares. PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K _______________________ CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 _______________________ • ZTlido net sales for the month ended June 30, 2024 were in the range of $7.5 million to $9.0 million, compared to $4.4 million for the same period last year, representing growth in the range of approximately ...

Investors and Media Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 Office: (650) 516-4310 ZTlido® net sales for the month of June 2024 grew in the range of 70% to 104%, compared to the same period last year. ZTlido® net sales for the quarter ended June 2024 grew in the range of 28% to 42%, compared to the same period last year. Total product net sales for the month of June 2024 grew in the range of 77% to 116%, compared to the same period last year. Total product net sales for the quarter e ...

"The commercialization of Scilex's three non-opioid products continues on schedule and we anticipate growth to accelerate through this year and beyond 2024. Given our accelerated pace of product growth, we are aggressively implementing our strategy of building out additional logistics and distribution for our commercial products. Signing an additional distribution partner at this point sets the stage for a successful and aggressive product launch into specialized point of care customers. We will continue to ...

PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly resp ...